John G. Ullman & Associates’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.3M Sell
94,272
-7,050
-7% -$814K 1.5% 16
2025
Q4
$10.7M Buy
101,322
+2,616
+3% +$246K 1.42% 19
2025
Q3
$8.28M Buy
98,706
+4,393
+5% +$362K 1.12% 26
2025
Q2
$7.47M Buy
94,313
+396
+0.4% +$31.5K 1.11% 24
2025
Q1
$8.43M Sell
93,917
-2,506
-3% -$234K 1.3% 19
2024
Q4
$9.59M Sell
96,423
-1,049
-1% -$108K 1.41% 16
2024
Q3
$11.1M Buy
97,472
+1
+0% +$119 1.59% 15
2024
Q2
$12.1M Sell
97,471
-728
-0.7% -$93.8K 1.84% 14
2024
Q1
$13M Sell
98,199
-600
-0.6% -$74K 1.99% 15
2023
Q4
$10.8M Sell
98,799
-1,070
-1% -$111K 1.71% 17
2023
Q3
$10.3M Sell
99,869
-950
-0.9% -$102K 1.68% 15
2023
Q2
$11.6M Sell
100,819
-872
-0.9% -$99K 1.79% 14
2023
Q1
$10.8M Sell
101,691
-663
-0.6% -$71.6K 1.68% 16
2022
Q4
$11.4M Sell
102,354
-31,118
-23% -$3.18M 1.81% 13
2022
Q3
$11.5M Sell
133,472
-1,447
-1% -$129K 2.01% 11
2022
Q2
$12.3M Buy
134,919
+32
+0% +$2.84K 1.97% 12
2022
Q1
$11.1M Buy
134,887
+104
+0.1% +$8.2K 1.53% 21
2021
Q4
$10.3M Buy
134,783
+7,260
+6% +$578K 1.42% 25
2021
Q3
$9.58M Buy
127,523
+48,100
+61% +$3.66M 1.3% 31
2021
Q2
$6.18M Sell
79,423
-4,336
-5% -$323K 0.8% 39
2021
Q1
$6.16M Sell
83,759
-944
-1% -$69.6K 0.83% 39
2020
Q4
$6.61M Sell
84,703
-610
-0.7% -$46.7K 1.02% 35
2020
Q3
$6.75M Sell
85,313
-140
-0.2% -$11K 1.4% 26
2020
Q2
$6.3M Sell
85,453
-401
-0.5% -$30.2K 1.54% 22
2020
Q1
$6.3M Sell
85,854
-151
-0.2% -$11.9K 1.67% 20
2019
Q4
$7.46M Sell
86,005
-2,096
-2% -$172K 1.28% 24
2019
Q3
$7.08M Sell
88,101
-1,686
-2% -$135K 1.29% 26
2019
Q2
$7.18M Sell
89,787
-57,012
-39% -$4.37M 1.26% 28
2019
Q1
$11.7M Sell
146,799
-59,669
-29% -$4.46M 2.11% 12
2018
Q4
$15.1M Sell
206,468
-56,017
-21% -$3.95M 3.04% 6
2018
Q3
$17.8M Sell
262,485
-1,153
-0.4% -$73.5K 3.23% 5
2018
Q2
$15.3M Buy
263,638
+13,284
+5% +$749K 2.89% 8
2018
Q1
$13M Buy
250,354
+36,386
+17% +$1.97M 2.52% 9
2017
Q4
$11.5M Sell
213,968
-3,145
-1% -$174K 2.29% 11
2017
Q3
$13.3M Sell
217,113
-3,283
-1% -$199K 2.59% 11
2017
Q2
$13.5M Sell
220,396
-2,463
-1% -$150K 2.67% 7
2017
Q1
$13.5M Sell
222,859
-2,274
-1% -$138K 2.79% 8
2016
Q4
$12.6M Sell
225,133
-2,594
-1% -$152K 2.65% 9
2016
Q3
$13.6M Sell
227,727
-5,712
-2% -$334K 2.79% 8
2016
Q2
$12.8M Sell
233,439
-3,065
-1% -$163K 2.64% 8
2016
Q1
$11.9M Buy
236,504
+2,976
+1% +$146K 2.8% 8
2015
Q4
$11.8M Buy
233,528
+10,452
+5% +$527K 2.6% 9
2015
Q3
$10.5M Buy
223,076
+24,544
+12% +$1.3M 2.49% 9
2015
Q2
$10.8M Sell
198,532
-9,736
-5% -$546K 2.03% 10
2015
Q1
$11.4M Sell
208,268
-4,166
-2% -$236K 2.17% 11
2014
Q4
$11.5M Sell
212,434
-2,594
-1% -$145K 2.17% 11
2014
Q3
$12.2M Sell
215,028
-4,223
-2% -$237K 2.34% 9
2014
Q2
$12.1M Sell
219,251
-5,030
-2% -$274K 2.21% 9
2014
Q1
$12.1M Buy
224,281
+864
+0.4% +$44.7K 2.25% 9
2013
Q4
$10.7M Buy
223,417
+12,767
+6% +$584K 2.04% 10
2013
Q3
$9.57M Sell
210,650
-1,553
-0.7% -$70.9K 1.95% 13
2013
Q2
$9.4M Buy
+212,203
New +$9.48M 1.96% 11

Other funds holding MRK

John G. Ullman & Associates's MRK Position: Q1 2026 in Review

John G. Ullman & Associates reduced its Merck (MRK) stake by 7% in Q1 2026, selling an estimated $814K and leaving 94,272 shares worth $11.3M. The position accounts for 1.5% of the portfolio, ranked #16.

John G. Ullman & Associates first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.8M in Q3 2018. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • John G. Ullman & Associates held 94,272 shares of Merck worth $11.3M as of Q1 2026.
  • John G. Ullman & Associates sold 7,050 Merck shares in Q1 2026, an estimated $814K.
  • Merck made up 1.5% of John G. Ullman & Associates's portfolio in Q1 2026, its #16 holding.
  • John G. Ullman & Associates first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • John G. Ullman & Associates's Merck position peaked at $17.8M in Q3 2018.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on John G. Ullman & Associates's 13F filing for Q1 2026, filed 6 May 2026.